• DOI:10.1510/ICVTS.2006.129171
• Corpus ID: 8139579

Elevated anti-cholesterol antibody levels in the sera of non-small cell lung cancer patients.

@article{Egri2006ElevatedAA,
  title={Elevated anti-cholesterol antibody levels in the sera of non-small cell lung cancer patients.},
  author={G{\'a}bor Egri and Iren Orosz},
  journal={Interactive cardiovascular and thoracic surgery},
  year={2006},
  volume={5 5},
  pages={
          649-51
        }
}

• G. Egri, I. Orosz
• Published 1 October 2006
• Medicine, Biology
• Interactive cardiovascular and thoracic surgery

There have been no published data yet on the serum level of antibodies against cholesterol (anti-cholesterol antibodies) in oncological patients. We decided to examine these levels in the sera of non-small cell lung cancer (NSCLC) patients. Measurements were performed by ELISA technique in the sera of 44 NSCLC patients and the results were compared to the anti-cholesterol antibody levels of 34 non-tumorous control subjects. Serum anti-cholesterol antibody levels were found to be significantly higher in NSCLC patients than in non-tumorous controls (40.35 arbitrary units/ml (AU/ml) versus 26.00 AU/ml, P=0.0003). The elevated anti-cholesterol antibody values were observable at different percentile values as well (25 percentile: 27.01 AU/ml in NSCLC patients, versus 17.33 AU/ml in controls; 75 percentile: 60.90 AU/ml in NSCLC patients versus 32.90 AU/ml in controls). These results suggest that anti-cholesterol antibodies might be applicable for the serodiagnosis of NSCLC. We emphasize the need for the collection of more data on anti-cholesterol antibody levels in NSCLC patients and in patients with different other malignant tumours in order to investigate the possible benefit anti-cholesterol antibodies might offer in clinical work.